The present invention provides methods for diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessement/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the asessement of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different pathophysiological events cardiac function and represent a potential target for therapeutical approaches.
|Published - 20 Dec 2018